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Introduction
Cancer metastasis is thought to be an inefficient process, requiring a complex set of interactions between tumor cells and the host leading to development of a grossly demonstrable secondary. A commonly described model of metastasis holds that once neoplastic cells leave a primary tumor and reach the circulation, a series of hurdles must be overcome to establish a metastatic deposit. These hurdles include evasion of host immune surveillance, arrest within a distant capillary bed, adherence to endothelial cells of the target organ, invasion across the endothelial basement membrane, proliferation of both neoplastic and stromal cells at the secondary site, and neovascularization (1) . This metastatic cascade model provides a framework for the study of the regulation of metastasis and may provide insights into novel therapeutic strategies. While considerable experimental evidence lends support to the postulated roles of adhesion molecules, proteolytic enzymes, and both autocrine and paracrine growth factors in the process of metastasis (2) , the contribution of angiogenesis to secondary tumor formation has principally been inferred from numerous investigations of models of subcutaneous tumor growth (3) . The ability of a primary tumor to induce angiogenesis appears to reflect a balance between positive and negative regulatory factors (4) and is felt to represent a fundamental element in the control of tumor growth beyond 2-3 mm in greatest dimension. The majority of attention has been directed toward the identification of various peptide growth factors, elaborated by certain tumor cells, which exhibit direct angiogenic activity, as defined by their ability to stimulate proliferation and motility of endothelial cells in culture and to induce new blood vessel formation in rabbit cornea or chick chorioallantoic membrane assays (4) . Recently, considerable interest has developed in the possible participation of the endothelial mitogen vascular endothelial growth factor (VEGF)' in malignant tumor growth.
VEGF is a homodimeric glycoprotein consisting of four isoforms (containing either 121, 165, 189, or 206 amino acid residues in the mature monomer), which are generated by alternative splicing of mRNA derived from a single gene (5, 6) . While all forms of VEGF possess a signal sequence, only the smaller two species are secreted (5) . In contrast, the larger forms are associated with heparin-bound proteoglycans in the extracellular matrix (7) . VEGF is mitogenic for a variety of large and small vessel endothelial cells, induces the production of tissue factor, collagenase, plasminogen activators, and their inhibitors, and stimulates hexose transport in these cells as well (for review see reference 6). VEGF is also known as vascular permeability factor by virtue of its permeability enhancing effects (8) . VEGF gene expression has been demonstrated in several human cancer lines in vitro (9 ) and in surgically resected tumors of the human gastrointestinal tract (10), ovary (1 1), brain (12) , and kidney (13) . Recently, elevated serum levels of VEGF have been reported in patients with lung and gynecologic cancers (14) . Scatchard analysis of binding kinetics of '25I-VEGF to several types of bovine and human endothelial cells has indicated two classes of high affinity binding sites (15) , and two receptor tyrosine kinases have recently been identified for which VEGF acts as a high affinity ligand: the fms-like tyrosine kinase fltl (16) and KDR (17) . The importance of VEGF and its receptors in glioblastoma growth has recently been demonstrated in vivo. Kim et al. (18) reported that administration of neutralizing monoclonal antibody directed against human VEGF inhibited growth of subcutaneous human xenografts in the nude mouse, and Millauer (19) demonstrated growth suppression of the C6 rat glioblastoma in the nude mouse after local administration of retrovirus expressing a dominant negative mutant of flk-1, the murine homologue of KDR. In this investigation, we have examined the possible role of VEGF and its receptors in the growth of colorectal cancer metastases in the liver. While prominent tumor vascularity represents an important histologic hallmark of glioblastoma (12) , colorectal cancers generally are poorly vascularized and are not characterized by prominent perivascular edema. Nevertheless, VEGF mRNA was found to be ubiquitously expressed in human liver metastases from primary colon or rectal cancers as assessed by either Northern analysis or in situ hybridization. Both fltl and KDR mRNA could be demonstrated in hepatic metastases but not in the surrounding normal hepatic parenchyma. We also provide evidence, using neutralizing VEGF monoclonal antibodies, that VEGF serves a major function in hepatic tumorigenesis in an athymic mouse model of experimental liver metastasis. 
Methods

Cell lines and culture
The human colorectal carcinoma lines LS174T, HCT 15, SW 620, COLO 201, COLO 205, and COLO 320 (obtained from Dr. Young Kim, UCSF) were grown and maintained in DMEM supplemented with 10% fetal bovine serum, penicillin (100 U/ml) and streptomycin (100 Mg/ml) (complete DMEM), in a 5% CO2 environment unless otherwise indicated. LS LiM 6 is a derivative of LS 174T selected for its high liver metastasizing ability during cecal growth (24), and HM7 is a variant of LS 174T selected in vitro for high mucin production which also has a high liver-colonizing capacity after splenic-portal injection in athymic mice (25) . To determine the effect of rhVEGF on proliferation of colon carcinoma lines in vitro, 2,000 cells/well were cultured overnight in flat-bottom 96-well microtiter plates at 370C in complete DMEM. The medium was aspirated and fresh serum-free medium containing 0-100 ng/ml rhVEGF or 10 Mg/ml of mAb 4.6.1 was added to S replicate wells. Cells were cultured for 72 h, and cell number was estimated using the MTT assay (26) . For determination of VEGF secretion, the cell lines COLO 205, HCT 15 , and LS LiM6 were grown to confluence in 6-well tissue culture plates in complete DMEM. The cultures were washed with HBSS and replaced with 2.0 ml of fresh serum-free medium. Cells were maintained at 370C for 48 h, conditioned media were collected, cells were removed by centrifugation at 10,000 rpm for 10 min, and supernatants were stored at -70°C. VEGF immunoactivity was assayed in duplicate cultures by ELISA as previously described (21).
Cell migration assay
The effect of anti-VEGF on migration of colon carcinoma lines was demonstrated by using the microcarrier bead assay (27) . Briefly, a suspension of LS LiM6 cells was seeded into a 100-mm culture dish at 105 cells/ml in 20 ml of complete DMEM and 5 mg/ml dextran matrix beads (Cytodex 2; Pharmacia LKB Biotechnology, Piscataway, NJ). Bead cultures were incubated for 3 d, allowing cells to attach to beads and undergo 1-2 doublings. Attached cells were counted by removing a 1-ml aliquot from the bead culture, washed with Ca2/Mg2'-free phosphate-buffered saline, trypsinized (0.05% trypsin/0.02% EDTA in Ca2+/ Mg2+-free HBSS) to detach cells, and counted with hemacytometer. The bead suspension was adjusted to 2 x l05 cells/ml in serum-free DMEM, and 0.5 ml was seeded into 2-cm2 wells of 24-well plates. To each of six wells, 50 Mg/ml rhVEGF or epidermal growth factor (Sigma Chemical Co., St. Louis, MO), and 10 Mg/mI anti-VEGF mAb 4.6.1 or control mAb was added in a volume of 25 ml in various combinations as shown in Table I . Plates were incubated for 48 h, after which the wells were rinsed three times with PBS to remove beads, and the attached cells were stained with 1.0% crystal violet in deionized water. The cells were counted by optical microscopy using a Zeiss ID 02 microscope and x 10 objective. Data were expressed as cells per 10 fields.
RNA isolation and Northern analysis
All colon carcinoma lines were grown to confluence in complete DMEM in 2-cm tissue culture plates, and total cellular RNA was extracted using RNAzol B (Tel-Test, Inc.; Friendswood, TX). Total RNA from human tissues was prepared using the guanidinium isothiocyanate/cesium chloride gradient method (28). RNA (27) under serumfree conditions (Table I) . Neutralizing antibody to human VEGF had no effect on either basal or epidermal growth factor-stimulated migration of LS LiM6 cells. Also, the addition of exogenous VEGF (50 ng/ml) similarly led to no stimulation of baseline cell migration in this assay. These data suggest that the inhibition of human colon cancer growth in the nude mouse by antibody 4.6.1 is not a consequence of an inhibition of cancer cell proliferation or motility. Experimental hepatic metastases. The liver is typically the first and most frequent site of metastasis in colorectal cancer (30) . Consequently, an effective antineoplastic therapy in this disease must be capable of modulating tumor growth at this orthotopic site. We chose to use a previously established model of experimental liver metastasis from human colorectal cancer in the athymic mouse to investigate the contribution of VEGF to hepatic tumorigenesis (25) . The --t.
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-W WO1. 10 ;;Fw=t,>9s1 r ! estimated tumor volume per liver were 10-and 18-fold greater, respectively, in the control animals versus the anti-VEGFtreated mice (Table II) . Liver weights were also significantly greater in the control versus anti-VEGF-treated animals (3.68±1.25 g vs 1.09±0.04 g, respectively; P = 0.03). When the size distribution of liver tumors was examined, the influence of anti-VEGF therapy became even more evident. An average of 91% of tumors per liver in the anti-VEGF-treated mice was smaller than 1 mm and 6 out of 7 of these mice had no tumor (Fig. 6 ). As we observed in biopsied human liver tumors, human colon cancer xenografts in the mouse liver strongly expressed VEGF mRNA. VEGF expression was confined to the epithelial cells within each tumor and was equivalent in the control and anti-VEGF-treated animals (Fig. 6, a and b) . Background labeling with a VEGF sense riboprobe in the experimental mouse liver metastases was comparable with that demonstrated with the sense riboprobe in the human liver metastases, as in Fig. 2 b (data not shown). Strong labeling of tumor blood vessels was observed in the liver tumors of control antibody-treated mice, using the flk-1 antisense probe (Fig. 6 c) . However, no blood vessels were identified in the small hepatic metastases of the anti-VEGF-treated mice, and we observed no specific hybridization of the flk-1 probe in these tumors (Fig. 6 d) .
Discussion
Approximately 60,000 patients die each year in the United States from colorectal cancer, and 40,000 of these will have liver metastases as the principal site of disease (31). It is estimated that liver resection for colorectal secondaries is curative in only 1,000-1,500 of these individuals. Of the remaining patients, standard chemotherapeutic agents may be delivered either systemically or by regional infusion, but response rates do not exceed 50% and no patient is cured (32) . In an effort to better understand the biology of metastasis in colorectal cancer, we have tested the hypothesis that angiogenesis plays a fundamental role in the formation of liver metastases from human colorectal cancer, and that the endothelial cell mitogen VEGF may act as a major regulator of hepatic tumorigenesis in this disease.
In agreement with this hypothesis, Northern analysis of cultured human colon carcinoma demonstrated expression of VEGF mRNA to varying degrees in all cell lines tested. The cDNA probe hybridized predominantly to a 3.3-kb mRNA species which probably represents VEGF165 (5). Three of these lines were tested for VEGF secretion, and immunoreactive VEGF was identified in the conditioned media of these cells (COLO 205, HCT 15 , and LS LiM6) in amounts which were proportional to their expression of VEGF mRNA. Several other peptide growth factors have been reported to act as direct endothelial mitogens, including basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and transforming growth factor alpha (TGFa). bFGF has been well characterized as an angiogenic protein with a potency which is comparable with that of VEGF (33) . The expression of bFGF in primary human colorectal cancers is sparse, however, and immunoactivity resides principally in the stromal cells of these tumors (34) . While bFGF lacks a signal sequence and is not likely to act as a carcinoma-derived endothelial growth factor in human colorectal cancer, bFGF can be demonstrated in the extracellular matrix in many tissues and synergizes with VEGF using both in vitro and in vivo assays of angiogenesis (35) . Consequently, a contributory role of bFGF in colon cancer metastasis formation cannot be excluded. HGF, also called scatter factor, can stimulate endothelial cell proliferation and migration in vitro and is angiogenic in a rabbit cornea assay (36) . The HGF receptor, cMET, is overexpressed in colon cancers and may regulate the invasive behavior of these neoplasms (37) . However, HGF, the cMET ligand, appears to be expressed by stromal cells rather than the carcinoma cells within human colon cancer metastases (our unpublished observations). While TGFa is secreted by a variety of human colon cancer lines, this growth factor and its receptor are expressed at comparable levels in benign and malignant gastrointestinal epithelium (38). Expression of other potential angiogenic factors in human colorectal cancer remains to be investigated.
That the expression of VEGF in colon carcinoma is not restricted to tumor cell lines in vitro is demonstrated by the finding of strong VEGF gene expression by either Northern analysis or in situ hybridization in each of 30 liver metastases from colon or rectal primaries. VEGF mRNA was identified throughout each tumor examined, but was confined to the malignant cells of the neoplasm. These data are consistent with the finding of Brown and co-workers (10) of an enhanced expression of VEGF in primary colon cancers compared with matched normal colonic mucosa. Adjacent, histologically normal liver in these patients also expressed VEGF mRNA, although at levels which were considerably lower than those found in the hepatic tumors. In agreement with the report of Monacci et al. (39) in the rat, in situ hybridization studies of normal human liver revealed that VEGF mRNA was localized to hepatocytes and to a small number of scattered Kupffer cells. The function of hepatocyte-derived VEGF is not clear. It has been suggested that in addition to a possible role in development and differentiation of the vascular system, VEGF may contribute to maintenance of vascular integrity and physiologic homeostasis in the adult, particularly in tissues bearing fenestrated endothelium such as the kidney, spleen, and liver (40) . In addition to expression of the ligand, high affinity binding of 1251-VEGF to both small and large vessels in tissue sections of normal mouse liver has been reported (41) . In the present study, however, no specific hybridization of RNA probes for either known VEGF receptor was observed in histologically normal human liver. It is possible that expression of either KDR orflt occurs in the human liver at levels which are too low to be detected by in situ hybridization. Alternatively, VEGF may associate with binding sites in hepatic endothelial cells which are not encoded by KDR or fltl.
In contrast with the surrounding normal liver, expression of both VEGF receptor genes was identified in the majority of hepatic metastases in which tumor vessels were seen. Hybridization of the probes for KDR and fIth was limited to endothelial cells of both large and small vessels in the neoplasms. Since it has been shown that after splenic tumor injection the vascular supply of experimental hepatic metastases develops from hepatic sinusoids (42) While these data establish the presence of all elements of the VEGF system in metastatic colorectal cancer in humans, the in vivo studies provide evidence that this system is central to the formation and growth of hepatic secondary tumors. In a subcutaneous tumor model of human colon carcinoma in the nude mouse, intraperitoneal injection of neutralizing monoclonal antibody directed against VEGF delayed the onset of tumor formation and markedly diminished the rate of tumor growth in a dose-and time-related fashion. Using a mouse model of experimental liver metastases, the inhibitory effect of anti-VEGF treatment was even more pronounced. 4 wk after intrasplenic tumor inoculation, all animals had developed liver tumors. However, the anti-VEGF-treated animals contained significantly fewer and significantly smaller tumors than the control group. Most of the tumors in the treated group were under 1 mm in diameter and all were under 3 mm in greatest dimension. This finding corresponds well to the estimation by Folkman (49) that tumors require neovascularization for growth beyond a diameter of 2-3 mm.
The regimen of anti-VEGF administration in this investigation was begun 1 d after tumor inoculation and thus most closely resembles an adjuvant therapy. Future studies will examine the activity of a VEGF against established liver metastases in colorectal cancer. Targeting the tumor vasculature was first proposed by Folkman as a fundamentally novel approach to cancer treatment (49) . Various agents which may inhibit tumor angiogenesis have been identified which act directly upon endothelial cells to block the proliferative response to mitogens (4) . The present data emphasize, however, that despite the potential contribution of TGFa, HGF, and bFGF or other tumor-derived angiogenic growth factors, strategies designed to antagonize one specific endothelial mitogen, VEGF, may form the basis of an effective antineoplastic therapy in human colorectal cancer.
